REG - BiVictriX Therapcts. - Expansion of Therapeutic Pipeline

Bivictrix TherapeuticsAnnouncement

23/02/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220223:nRSW4803Ca&default-theme=true

RNS Number : 4803C  BiVictriX Therapeutics PLC  23 February 2022

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company")

 

 

BiVictriX announces expansion of its therapeutic pipeline with two additional
drug discovery programmes

 

Alderley Park, 23 February 2022 - BiVictriX Therapeutics plc (AIM: BVX), an
emerging biotechnology company applying a novel approach to develop next
generation cancer therapies using insights derived from frontline clinical
experience, today announces the expansion of the Company's therapeutic
pipeline with two additional programmes, BVX002 and BVX003, both entering the
early stages of drug development.

 

BVX002 and BVX003 target novel cancer-specific twin antigen fingerprints,
incorporating the Company's proprietary Bi-Cygni® technology, alongside the
established and validated Antibody Drug Conjugate (ADC) mechanism-of-action,
to form the next-generation of Bi-Cygni® ADCs with superior cancer
selectivity. These programmes enable the targeting of several haematological
and solid tumour cancer indications and will be developed alongside
BiVictriX's lead asset, BVX001, which has a lead indication in Acute Myeloid
Leukaemia (AML). This pipeline expansion demonstrates the broad utility of the
Bi-Cygni® approach across a wide range of solid tumour and haematological
cancer types which constitute areas of significant unmet medical need, and
further highlights the potential expansion of the platform in novel areas of
immuno-oncology.

 

The pipeline expansion follows the Company's recent filing of four new patent
applications to further strengthen its growing intellectual property portfolio
in the UK and internationally.  The patents, which will form part of a new
patent family for BiVictriX, relate to several novel cancer-specific antigen
pairs or "fingerprints" across a range of oncology indications, which have
been identified by the Company.

 

Tiffany Thorn, Chief Executive of BiVictriX, commented: "This is an exciting
announcement for the Company. The expansion of our current therapeutic
pipeline to include two additional programmes moving into the early stages of
development is a significant milestone and enables BiVictriX to demonstrate
the broad utility of its promising new approach to cancer therapeutic
development across a wide range of difficult-to-treat cancers, including both
solid tumour and haematological indications that currently represent areas of
urgent unmet medical need. We are focused on working to fast-track the
development of these two new programmes alongside our lead asset, BVX001, to
reach early preclinical proof of concept in the short to medium term."

 

   For more information, please contact:

BiVictriX Therapeutics plc
 Tiffany Thorn, Chief Executive Officer

 Iain Ross, Chairman                                Email: info@bivictrix.com (mailto:info@bivictrix.com)

 SP Angel Corporate Finance LLP (NOMAD and Broker)  Tel: +44 (0) 20 3470 0470
 David Hignell, Caroline Rowe (Corporate Finance)

 Vadim Alexandre, Rob Rees (Sales and Broking)

 Panmure Gordon (UK) Limited (Joint Broker)         Tel: +44 (0) 20 7886 2500
 Rupert Dearden/Freddy Crossley/Emma Earl

 Consilium Strategic Communications
 Mary-Jane Elliott, Genevieve Wilson, Alex Gunter   Tel: +44 (0) 20 3709 5700

                           Email: Bivictrix@consilium-comms.com (mailto:Bivictrix@consilium-comms.com)

 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is
focused on leveraging clinical experience to develop a class of highly
selective, next generation cancer therapeutics which exhibit superior potency,
whilst eliminating treatment-related toxicities.

 

The Company utilises a first-in-class approach to generate a proprietary
pipeline of Bi-Cygni® therapeutics which are designed to selectively target
antigen co-expression fingerprints, or "twin antigens", on tumour cells, which
are largely absent from healthy cells. Whereas this concept has been validated
in a clinical diagnostic setting to support the diagnosis and monitoring of
haematological cancers, it has not yet been widely used in a therapeutic
setting.

 

BiVictriX has identified a diverse panel of novel cancer-specific "twin
antigens", across a broad range of cancer indications including Diffuse Large
B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic
Cell Neoplasm. The Company is using these novel "twin-antigens" to develop
more effective and safer therapeutics to target cancers that are expected to
constitute orphan indications and currently constitute areas of high unmet
medical need.

 

Find out more about BiVictriX online at www.bivictrix.com
(http://www.bivictrix.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSEIFWEEESEEE